Related Experiment Video
Updated: May 28, 2026
07:37
An Adoptive Transfer Model of Rheumatoid Arthritis in Mice
Published on: June 6, 2025
[New treatments in pediatric rheumatology: effects, limits, and future developments]
1Unité d'immunologie-hématologie et rhumatologie pédiatriques, centre de référence national maladies rares « arthrites juvéniles », hôpital Necker-Enfants-Malades, université Paris-Descartes, 149, rue de Sèvres, 75015 Paris, France. quartier@necker.fr
Summary
Juvenile idiopathic arthritis (JIA) is complex, with targeted therapies like TNF-alpha inhibitors showing promise. Specialized care is crucial for managing JIA and its associated conditions, including uveitis.
Area of Science:
- Rheumatology
- Immunology
- Pediatrics
Context:
- Juvenile idiopathic arthritis (JIA) presents as a diverse set of autoimmune conditions.
- International research collaborations have facilitated clinical trials for novel JIA treatments.
Purpose:
- To review current therapeutic strategies for juvenile idiopathic arthritis (JIA).
- To highlight the use of biotherapies targeting specific inflammatory pathways in JIA.
- To emphasize the importance of specialized care and long-term monitoring for pediatric patients with JIA.
Summary:
- Biotherapies targeting tumor necrosis factor-alpha (TNF-alpha), interleukin-1 (IL-1), IL-6, or T-cell costimulation (abatacept) are utilized in JIA management.
- Chronic uveitis associated with JIA may necessitate experimental biotherapies, including anti-TNF-alpha monoclonal antibodies.
- Systemic-onset JIA (childhood-onset Still's disease) presents unique challenges, potentially requiring IL-1 or IL-6 antagonists.
Impact:
- Management of JIA requires coordinated care from pediatric specialists into adulthood.
- Close monitoring for long-term adverse effects is essential for newly introduced pediatric JIA treatments.
Related Concept Videos
01:24Pharmacokinetics in Pediatric Patients: Drug Metabolism
In pediatric care, understanding the nuances of hepatic drug metabolism is crucial, as it significantly differs from that of adults. This divergence is primarily due to the developmental stage of drug-metabolizing enzymes, which affects how medications are processed in the body. In neonates, for instance, the activity of Phase I enzymes—critical for the initial breakdown of drugs—is markedly reduced, functioning at just 20–40% of the levels seen in adults. This reduction poses a challenge in...
01:26Pharmacokinetics in Pediatric Patients: Drug Excretion
In pediatric medicine, understanding the renal function and drug elimination nuances is crucial for administering safe and effective treatments. Newborns, in particular, display markedly slower renal functions than adults, profoundly affecting how drugs are cleared from their bodies. This slower drug clearance requires clinicians to extend the dosing intervals for many medications to prevent drug accumulation and toxicity while ensuring therapeutic efficacy.One key area where these adjustments...
01:21Rheumatic Heart Disease III: Medical Management
Rheumatic heart disease (RHD) management can be divided into two main strategies: prevention and long-term management.Primary PreventionPrimary prevention focuses on timely diagnosis and management of group A streptococcal pharyngitis to prevent acute rheumatic fever. The most widely used antibiotic for treating this condition is intramuscular benzathine penicillin G.Acute Rheumatic Fever TreatmentThe primary treatment goal for a patient diagnosed with acute rheumatic fever is to suppress the...
01:29Inflammatory Bowel Disease IV: Pharmacological Management
Upon diagnosis, managing Inflammatory Bowel Disease (IBD) involves addressing several crucial aspects. The primary goals include resting the bowel, correcting malnutrition, and providing symptomatic relief. Resting the bowel may consist of medications to reduce inflammation and promote healing. Correcting malnutrition is essential, often requiring dietary adjustments and nutritional supplements. Symptomatic relief aims to ease pain, diarrhea, and other discomforts in IBD.
Pharmacologic...
Pharmacologic...
01:23Pharmacokinetics in Pediatric Patients: Overview and Drug Absorption
Understanding the physiological differences in the pediatric population is crucial for effective pharmacotherapy. Neonates, infants, and children exhibit significant variations in gastric pH, gastric emptying time, intestinal transit time, and biliary function. These variations profoundly affect oral drug absorption, necessitating a nuanced approach to pediatric dosing.Neonates present with a unique physiological profile, having a gastric pH greater than 4 and faster and more irregular gastric...
01:17Pharmacokinetics in Pediatric Patients: Drug Distribution
Drug distribution in the pediatric population exhibits unique challenges and considerations due to the physiological differences between children, particularly neonates and infants, and adults. A crucial aspect of pediatric pharmacology is understanding how these differences impact the pharmacokinetics of various drugs, necessitating age-specific dosing strategies to ensure efficacy and safety.Neonates and infants have a higher total body water content, ~75%–90% of their body weight, compared...